-
1
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), May 14-20 PubMed PMID: 15894097
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717. PubMed PMID: 15894097.
-
(2005)
Lancet
, vol.365
, Issue.9472
, pp. 1687-1717
-
-
-
2
-
-
67749114265
-
CYP2D6 and tamoxifen: DNA matters in breast cancer
-
Aug Review. PubMed PMID: 19629072
-
Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009 Aug;9(8):576-86. Review. PubMed PMID: 19629072.
-
(2009)
Nat Rev Cancer.
, vol.9
, Issue.8
, pp. 576-586
-
-
Hoskins, J.M.1
Carey, L.A.2
McLeod, H.L.3
-
3
-
-
67651177578
-
Genotype-guided tamoxifen therapy: Time to pause for reflection?
-
Aug Review. PubMed PMID: 19647203
-
Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 2009 Aug;10(8):825-33. Review. PubMed PMID: 19647203.
-
(2009)
Lancet Oncol.
, vol.10
, Issue.8
, pp. 825-833
-
-
Lash, T.L.1
Lien, E.A.2
Sørensen, H.T.3
Hamilton-Dutoit, S.4
-
4
-
-
70350752331
-
Genetic matters of CYP2D6 in breast cancer: Copy number variations and nucleotide polymorphisms
-
Nov PubMed PMID: 19866496
-
Yu KD, Shao ZM. Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms. Nat Rev Cancer. 2009 Nov;9(11):842. PubMed PMID: 19866496.
-
(2009)
Nat Rev Cancer.
, vol.9
, Issue.11
, pp. 842
-
-
Yu, K.D.1
Shao, Z.M.2
-
5
-
-
67650874081
-
Cancer statistics, 2009
-
Jul-Aug Epub 2009 May 27. PubMed PMID: 19474385
-
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. Epub 2009 May 27. PubMed PMID: 19474385.
-
(2009)
CA Cancer J Clin.
, vol.59
, Issue.4
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Thun, M.J.6
-
6
-
-
84862299221
-
Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
-
(Tufts EPC). Project ID: GEN609. December 8
-
Teruhiko Terasawa T, Dahabreh IJ, Castaldi PD, Trikalinos TA. (Tufts EPC). Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report. Project ID: GEN609. December 8, 2009.
-
(2009)
Technology Assessment Report
-
-
Teruhiko Terasawa, T.1
Dahabreh, I.J.2
Castaldi, P.D.3
Trikalinos, T.A.4
-
7
-
-
67650333853
-
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
-
American Society of Clinical Oncology Jul 1 Epub 2009 May 26. PubMed PMID: 19470930; PubMed Central PMCID: PMC2716943
-
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009 Jul 1;27(19):3235-58. Epub 2009 May 26. PubMed PMID: 19470930; PubMed Central PMCID: PMC2716943.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.19
, pp. 3235-3258
-
-
Visvanathan, K.1
Chlebowski, R.T.2
Hurley, P.3
Col, N.F.4
Ropka, M.5
Collyar, D.6
Morrow, M.7
Runowicz, C.8
Pritchard, K.I.9
Hagerty, K.10
Arun, B.11
Garber, J.12
Vogel, V.G.13
Wade, J.L.14
Brown, P.15
Cuzick, J.16
Kramer, B.S.17
Lippman, S.M.18
-
8
-
-
35248854448
-
Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs)
-
Jan;. Review. PubMed PMID: 17764209
-
Matchar DB, Thakur ME, Grossman I, McCrory DC, Orlando LA, Steffens DC, Goldstein DB, Cline KE, Gray RN. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evid Rep Technol Assess (Full Rep). 2007 Jan;(146):1-77. Review. PubMed PMID: 17764209.
-
(2007)
Evid Rep Technol Assess (Full Rep)
, Issue.146
, pp. 1-77
-
-
Matchar, D.B.1
Thakur, M.E.2
Grossman, I.3
McCrory, D.C.4
Orlando, L.A.5
Steffens, D.C.6
Goldstein, D.B.7
Cline, K.E.8
Gray, R.N.9
-
9
-
-
70349929431
-
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
-
Oct 7 PubMed PMID: 19809024
-
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009 Oct 7;302(13):1429-36. PubMed PMID: 19809024.
-
(2009)
JAMA.
, vol.302
, Issue.13
, pp. 1429-1436
-
-
Schroth, W.1
Goetz, M.P.2
Hamann, U.3
Fasching, P.A.4
Schmidt, M.5
Winter, S.6
Fritz, P.7
Simon, W.8
Suman, V.J.9
Ames, M.M.10
Safgren, S.L.11
Kuffel, M.J.12
Ulmer, H.U.13
Boländer, J.14
Strick, R.15
Beckmann, M.W.16
Koelbl, H.17
Weinshilboum, R.M.18
Ingle, J.N.19
Eichelbaum, M.20
Schwab, M.21
Brauch, H.22
more..
-
10
-
-
76749165728
-
Association between CYP2D6 polymorphisms and breast cancer outcomes
-
author reply 517 PubMed PMID: 20145226. Feb 10
-
Lash TL. Association between CYP2D6 polymorphisms and breast cancer outcomes. JAMA. 2010 Feb 10;303(6):516; author reply 517. PubMed PMID: 20145226.
-
(2010)
JAMA.
, vol.303
, Issue.6
, pp. 516
-
-
Lash, T.L.1
-
11
-
-
77950502100
-
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients
-
Mar 10 Epub 2010 Feb 1. PubMed PMID: 20124171
-
Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010 Mar 10;28(8):1287-93. Epub 2010 Feb 1. PubMed PMID: 20124171.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.8
, pp. 1287-1293
-
-
Kiyotani, K.1
Mushiroda, T.2
Imamura, C.K.3
Hosono, N.4
Tsunoda, T.5
Kubo, M.6
Tanigawara, Y.7
Flockhart, D.A.8
Desta, Z.9
Skaar, T.C.10
Aki, F.11
Hirata, K.12
Takatsuka, Y.13
Okazaki, M.14
Ohsumi, S.15
Yamakawa, T.16
Sasa, M.17
Nakamura, Y.18
Zembutsu, H.19
|